1984
DOI: 10.1016/0360-3016(84)90206-2
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic factors and changing trends in the treatment of stage I endometrial cancer: A clinical and histopathological study of 182 patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
12
0
2

Year Published

1989
1989
2011
2011

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(15 citation statements)
references
References 12 publications
1
12
0
2
Order By: Relevance
“…Many prior studies have also linked younger age to lower-risk clinicopathologic prognostic factors. [1][2][3][4][5][6] However, these results concerning uterine cancer in reproductive-age women have been challenged in recent studies. 8,9 In fact, some studies have shown that younger women may have more poor prognostic tumors with a worse outcome.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Many prior studies have also linked younger age to lower-risk clinicopathologic prognostic factors. [1][2][3][4][5][6] However, these results concerning uterine cancer in reproductive-age women have been challenged in recent studies. 8,9 In fact, some studies have shown that younger women may have more poor prognostic tumors with a worse outcome.…”
Section: Discussionmentioning
confidence: 99%
“…The improved survival of the younger women may be attributed to the earlier stage and lower grade of disease at presentation. [1][2][3][4][5][6] In contrast, other studies have demonstrated that younger patients have more adverse pathologic and prognostic factors. Gitsch et al 7 demonstrated that a proportion of younger patients have advanced disease as well as a higher rate of lymph node metastasis and synchronous ovarian primaries.…”
mentioning
confidence: 98%
“…The median survival of 10 patients was 4 months (range, 1-68 months); 2 patients treated with surgical resection and WBRT survived 60 months. The data from the literature shows that patient survival after the diagnosis of HM to the brain is poor, with a median survival time of usually less than 2 months (range, 0.2-83 months) [2,14,15,22,33,45]. Long-term survival is rare but has been documented in some patients with solitary brain lesions who underwent surgical resection and WBRT [15,32,43,45,50].…”
Section: Hm To the Brainmentioning
confidence: 99%
“…In drei grossen prospektiv randomisierten Studien [87][88][89] und mehreren retrospektiven Analysen [90][91][92][93][94][95] wurde der Stellenwert der adjuvanten perkutanen Radiatio bei Patientinnen mit Endometriumkarzinom untersucht. In allen Arbeiten konnte gezeigt werden, dass das Gesamtüberleben nach adjuvanter perkutaner Strahlentherapie nicht signifi kant verbessert war, jedoch die lokale Kontrolle.…”
Section: Lne Versus Perkutane Radiatiounclassified
“…Die Komplikationsrate war im Strahlentherapiearm signifi kant höher [88,89] . Unterschiedlich wurde in allen Studien die LNE gehandhabt: während bei Aalders et al [87] und in der POR-TEC-Studie [88] keine LNE durchgeführt wurde, erfolgte in der GOG-99-Studie [89] die pelvine/paraaortale LNE, auf deren Bedeutung in der Auswertung der Studie aber explizit nicht eingegangen wird. In den Untersuchungen von Straughn et al [95] und Fanning et al [91] erfolgten eine pelvine und paraaortale LNE, in der COSA-NZ-UK-Studie [94] nur eine pelvine LNE und bei Larson et al [90] eine pelvine und paraaortale LNE in Hochrisikosituationen.…”
Section: Lne Versus Perkutane Radiatiounclassified